Zaiding Pharmaceutical announced on December 13th that Wei Weijia& Reg; (Agamod) α Injection (Wei Weijia) has been included in the 2023 National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalogue (National Medical Insurance Drug Catalogue) released by the National Medical Security Administration of China. Wei Weijia has been included in the national medical insurance drug list for the first time, for the treatment of adult patients with generalized myasthenia gravis (gMG) who are positive for acetylcholine receptor (AChR) antibodies. Including Wei Weijia, the company currently has four products included in the national medical insurance drug catalog.